Fan Therapy for Alleviating Dyspnea in Adults: A Systematic Review and Meta-Analysis.

J Clin NursMay 22, 2026 (epub)
Clinical ResearchPulmonologyInternal Medicine (General)Open access

Ting Yu, Yijing Li, Shanshan Liu et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the effectiveness of fan therapy for alleviating dyspnea in adults, analyzing 15 studies with 623 participants. While the overall effect on dyspnea severity was not statistically significant, a significant short-term reduction was observed within 5-10 minutes after therapy (SMD = -0.41, p = 0.007).

Key findings

  • No statistically significant overall effect on dyspnea severity was found.
  • Significant short-term reduction in dyspnea severity within 5-10 minutes (SMD = -0.41, p = 0.007).
  • No significant differences in physiological parameters or physical activity levels were observed.
  • Qualitative evidence showed positive perceptions of fan therapy among patients and caregivers.

Why it matters

Understanding nonpharmacologic interventions like fan therapy can enhance symptom management strategies for dyspnea, particularly in settings where resources are limited. Its acceptability and low cost make it a practical option.

Source

PubMed · PMID 42174753Free full text on PubMed Central

Published in J Clin Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pulmonology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.